Home HIV	FAQ My Amedeo About	Flying Publisher
	Amedeo Prize 2008 The 21 Finalists

Schizophrenia

Free Subscription Articles published in Neuropsychopharmacology Retrieve available abstracts of 47 articles: HTML format

Single Articles

April 2008
1. KEGELES LS , Slifstein M, Frankle WG, Xu X, et al
   Dose-Occupancy Study of Striatal and Extrastriatal Dopamine D(2) Receptors by Aripiprazole in Schizophrenia with PET and [(18)F]Fallypride.
   Neuropsychopharmacology. 2008;.
   PubMed     Related articles    Abstract available
   
   
   March 2008
2. KATSEL P , Davis KL, Li C, Tan W, et al
   Abnormal Indices of Cell Cycle Activity in Schizophrenia and their Potential Association with Oligodendrocytes.
   Neuropsychopharmacology. 2008;.
   PubMed     Related articles    Abstract available
   
   
   February 2008
3. ERRITZOE D , Rasmussen H, Kristiansen KT, Frokjaer VG, et al
   Cortical and Subcortical 5-HT(2A) Receptor Binding in Neuroleptic-Naive First-Episode Schizophrenic Patients.
   Neuropsychopharmacology. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
4. SARTORIUS LJ , Weinberger DR, Hyde TM, Harrison PJ, et al
   Expression of a GRM3 Splice Variant is Increased in the Dorsolateral Prefrontal Cortex of Individuals Carrying a Schizophrenia Risk SNP.
   Neuropsychopharmacology. 2008;.
   PubMed     Related articles    Abstract available
   
   
   January 2008
5. BECKER TM , Kerns JG, Macdonald AW 3rd, Carter CS, et al
   Prefrontal Dysfunction in First-Degree Relatives of Schizophrenia Patients during a Stroop Task.
   Neuropsychopharmacology. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
6. BERGER GE , Wood SJ, Wellard RM, Proffitt TM, et al
   Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study.
   Neuropsychopharmacology. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
7. XUAN J , Zhao X, He G, Yu L, et al
   Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study.
   Neuropsychopharmacology. 2008;33:305-11.
   PubMed     Related articles    Abstract available
   
   
   December 2007
8. BUSTILLO JR , Rowland LM, Jung R, Brooks WM, et al
   Proton Magnetic Resonance Spectroscopy During Initial Treatment With Antipsychotic Medication in Schizophrenia.
   Neuropsychopharmacology. 2007;.
   PubMed     Related articles    Abstract available
   
   
   
9. MARTINEZ V , Sarter M
   Detection of the Moderately Beneficial Cognitive Effects of Low-Dose Treatment with Haloperidol or Clozapine in an Animal Model of the Attentional Impairments of Schizophrenia.
   Neuropsychopharmacology. 2007;.
   PubMed     Related articles    Abstract available
   
   
   
10. HAUPT DW , Fahnestock PA, Flavin KA, Schweiger JA, et al
    Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients.
    Neuropsychopharmacology. 2007;32:2561-9.
    PubMed     Related articles    Abstract available
    
    
    November 2007
11. CARPENTER WT , Koenig JI
    The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
12. BENEYTO M , Meador-Woodruff JH
    Lamina-Specific Abnormalities of NMDA Receptor-Associated Postsynaptic Protein Transcripts in the Prefrontal Cortex in Schizophrenia and Bipolar Disorder.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
13. LAVOIE S , Murray MM, Deppen P, Knyazeva MG, et al
    Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
14. ZHANG XY , Zhou DF, Wu GY, Cao LY, et al
    BDNF Levels and Genotype are Associated with Antipsychotic-Induced Weight Gain in Patients with Chronic Schizophrenia.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    October 2007
15. SOLIMAN A , O'Driscoll GA, Pruessner J, Holahan AL, et al
    Stress-Induced Dopamine Release in Humans at Risk of Psychosis: a [(11)C]Raclopride PET Study.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
16. HONG LE , Wonodi I, Lewis J, Thaker GK, et al
    Nicotine Effect on Prepulse Inhibition and Prepulse Facilitation in Schizophrenia Patients.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
17. LOPEZ-GIL X , Babot Z, Amargos-Bosch M, Sunol C, et al
    Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat.
    Neuropsychopharmacology. 2007;32:2087-97.
    PubMed     Related articles    Abstract available
    
    
    
18. MORICE E , Billard JM, Denis C, Mathieu F, et al
    Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia.
    Neuropsychopharmacology. 2007;32:2108-16.
    PubMed     Related articles    Abstract available
    
    
    September 2007
19. LEWIS DA , Gonzalez-Burgos G
    Neuroplasticity of Neocortical Circuits in Schizophrenia.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
20. LEUCHT S , Davis JM, Engel RR, Kane JM, et al
    Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs.
    Neuropsychopharmacology. 2007;32:1903-10.
    PubMed     Related articles    Abstract available
    
    
    August 2007
21. DAWSON LA , Cato KJ, Scott C, Watson JM, et al
    In Vitro and In Vivo Characterization of the Non-peptide NK(3) Receptor Antagonist SB-223412 (Talnetant): Potential Therapeutic Utility in the Treatment of Schizophrenia.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    July 2007
22. KEEFE RS , Malhotra AK, Meltzer HY, Kane JM, et al
    Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
23. SCHOLES KE , Harrison BJ, O'Neill BV, Leung S, et al
    Acute serotonin and dopamine depletion improves attentional control: findings from the stroop task.
    Neuropsychopharmacology. 2007;32:1600-10.
    PubMed     Related articles    Abstract available
    
    
    June 2007
24. SZESZKO PR , Robinson DG, Ashtari M, Vogel J, et al
    Clinical and Neuropsychological Correlates of White Matter Abnormalities in Recent Onset Schizophrenia.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    May 2007
25. EASTWOOD SL , Harrison PJ
    Decreased mRNA Expression of Netrin-G1 and Netrin-G2 in the Temporal Lobe in Schizophrenia and Bipolar Disorder.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
26. GOFF DC , Lamberti JS, Leon AC, Green MF, et al
    A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
27. JENSEN J , Willeit M, Zipursky RB, Savina I, et al
    The Formation of Abnormal Associations in Schizophrenia: Neural and Behavioral Evidence.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
28. WANG CZ , Johnson KM
    The role of caspase-3 activation in phencyclidine-induced neuronal death in postnatal rats.
    Neuropsychopharmacology. 2007;32:1178-94.
    PubMed     Related articles    Abstract available
    
    
    
29. BARAK S , Weiner I
    Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor.
    Neuropsychopharmacology. 2007;32:989-99.
    PubMed     Related articles    Abstract available
    
    
    April 2007
30. MAMO D , Kapur S, Keshavan M, Laruelle M, et al
    D(2) Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography: An Open-label Study in Patients with Schizophrenia.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
31. MEYER U , Nyffeler M, Schwendener S, Knuesel I, et al
    Relative Prenatal and Postnatal Maternal Contributions to Schizophrenia-Related Neurochemical Dysfunction after In Utero Immune Challenge.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
32. BARR RS , Culhane MA, Jubelt LE, Mufti RS, et al
    The Effects of Transdermal Nicotine on Cognition in Nonsmokers with Schizophrenia and Nonpsychiatric Controls.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    March 2007
33. RUBIN LH , Haas GL, Keshavan MS, Sweeney JA, et al
    Sex Difference in Cognitive Response to Antipsychotic Treatment in First Episode Schizophrenia.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    February 2007
34. VAN HAREN NE , Hulshoff Pol HE, Schnack HG, Cahn W, et al
    Focal Gray Matter Changes in Schizophrenia across the Course of the Illness: A 5-Year Follow-Up Study.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
35. SMESNY S , Rosburg T, Baur K, Rudolph N, et al
    Cannabinoids Influence Lipid-Arachidonic Acid Pathways in Schizophrenia.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
36. BENEYTO M , Kristiansen LV, Oni-Orisan A, McCullumsmith RE, et al
    Abnormal Glutamate Receptor Expression in the Medial Temporal Lobe in Schizophrenia and Mood Disorders.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
37. BALLMAIER M , Bortolato M, Rizzetti C, Zoli M, et al
    Cannabinoid Receptor Antagonists Counteract Sensorimotor Gating Deficits in the Phencyclidine Model of Psychosis.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
38. KOZAK R , Martinez V, Young D, Brown H, et al
    Toward a Neuro-Cognitive Animal Model of the Cognitive Symptoms of Schizophrenia: Disruption of Cortical Cholinergic Neurotransmission Following Repeated Amphetamine Exposure in Attentional Task-Performing, but Not Non-Performing, Rats.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
39. FRAU R , Orru M, Fa M, Casti A, et al
    Effects of topiramate on the prepulse inhibition of the acoustic startle in rats.
    Neuropsychopharmacology. 2007;32:320-31.
    PubMed     Related articles    Abstract available
    
    
    
40. RASKIND MA , Burke BL, Crites NJ, Tapp AM, et al
    Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
    Neuropsychopharmacology. 2007;32:284-8.
    PubMed     Related articles    Abstract available
    
    
    January 2007
41. ZHANG XY , Tan YL, Zhou DF, Haile CN, et al
    Nicotine Dependence, Symptoms and Oxidative Stress in Male Patients with Schizophrenia.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
42. EHLIS AC , Herrmann MJ, Pauli P, Stoeber G, et al
    Improvement of Prefrontal Brain Function in Endogenous Psychoses Under Atypical Antipsychotic Treatment.
    Neuropsychopharmacology. 2007;.
    PubMed     Related articles    Abstract available
    
    
    December 2006
43. GOLDMAN MB , Gnerlich J, Hussain N
    Neuroendocrine Responses to a Cold Pressor Stimulus in Polydipsic Hyponatremic and in Matched Schizophrenic Patients.
    Neuropsychopharmacology. 2006;.
    PubMed     Related articles    Abstract available
    
    
    November 2006
44. AGID O , Mamo D, Ginovart N, Vitcu I, et al
    Striatal Vs Extrastriatal Dopamine D(2) Receptors in Antipsychotic Response-A Double-Blind PET Study in Schizophrenia.
    Neuropsychopharmacology. 2006;.
    PubMed     Related articles    Abstract available
    
    
    October 2006
45. FEATHERSTONE RE , Rizos Z, Nobrega JN, Kapur S, et al
    Gestational Methylazoxymethanol Acetate Treatment Impairs Select Cognitive Functions: Parallels to Schizophrenia.
    Neuropsychopharmacology. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
46. LEUCHT S , Kane JM, Etschel E, Kissling W, et al
    Linking the PANSS, BPRS, and CGI: clinical implications.
    Neuropsychopharmacology. 2006;31:2318-25.
    PubMed     Related articles    Abstract available
    
    
    September 2006
47. KESSLER RM , Ansari MS, Riccardi P, Li R, et al
    Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.
    Neuropsychopharmacology. 2006;31:1991-2001.
    PubMed     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Bernd Sebastian Kamps website.    Design: